Kisspeptin-10 vs PT-141
Research Verdict
PT-141 is the stronger research reference for the stated comparison criteria. PT-141/bremelanotide: FDA approved (Vyleesi) for HSDD in premenopausal women 2019 - multiple Phase 2/3 RCTs.
Quick Answers
Which is better, Kisspeptin-10 or PT-141?
PT-141 is the stronger research reference for the stated comparison criteria. PT-141/bremelanotide: FDA approved (Vyleesi) for HSDD in premenopausal women 2019 - multiple Phase 2/3 RCTs.
What is the key difference between Kisspeptin-10 and PT-141?
PT-141 works via MC4R central arousal pathway; kisspeptin-10 works via GnRH pulsatility upstream of reproductive hormone axis - completely different targets with no mechanistic overlap.
Evidence Comparison
PT-141/bremelanotide: FDA approved (Vyleesi) for HSDD in premenopausal women 2019 - multiple Phase 2/3 RCTs. Kisspeptin-10: Phase 2 human data in hypothalamic amenorrhea and fertility (Jayasena 2014), but primarily studied as kisspeptin-54; kisspeptin-10-specific human data is limited. PT-141 wins on regulatory evidence.
Evidence Context Favoring Kisspeptin-10
GnRH pulsatility research, hypothalamic amenorrhea, or fertility applications targeting the HPG axis upstream.
Evidence Context Favoring PT-141
Sexual dysfunction research with regulatory approval requirement; bremelanotide is the only approved option in this class.
Side-by-Side Snapshot
| Evidence grade | Kisspeptin-10: Level B PT-141: Level A |
|---|---|
| Research status | Kisspeptin-10: Phase 2 PT-141: FDA Approved |
| Primary category | Kisspeptin-10: Sexual Health PT-141: Sexual Health |
| Cited studies | Kisspeptin-10: 2 PT-141: 2 |